The travails of the D. Blech companies aside, share price pressures in the sector in recent weeks more likely have resulted from the unwinding of Oppenheimer's Global Bio-Tech Fund, which has halved its biotech position from about $150 million since early July.

Following Oppenheimer's decision in July to avoid the volatility associated with